• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

MR BHAVESH PATEL, Managing Director, Marck Biosciences, at a press conference in Bangalore on Tuesday. — Sampath Kumar G.P.

Bangalore May 22 Marck Biosciences on Tuesday announced it was investing Rs 72 crore to augment its capacity of parenterals to target the Southern States, which account for 28 per cent of the Rs 1,600-crore market.

The company, which aims to achieve a revenue of Rs 25 crore (or eight per cent) of the Rs 440-crore market in the region, has launched a comprehensive range of products in Karnataka, which include common solutions, electrolyte replacements, antibiotic solutions, anti-fungal drug therapeutics, injectibles and eye and ear solutions. The products will be rolled out in other States in the region soon. Addressing a press conference here, Mr Bhavesh Patel, Managing Director, said that

Marck would be appointing distributors to serve both the retail and institutional markets, which were growing at a faster pace.

With its enhanced capacity of 230 million units of small volume parenterals and 61 million large volume parenterals, Marck has targeted an overall turnover of Rs 100 crore during the current fiscal, of which it hopes exports would be Rs 22 crore to customers in Africa, Latin America and new markets in South-East Asia. Contract manufacturing would account for Rs 18 crore during the year.

Mr Patel said with the current expansion Marck was gearing up to capitalise on the surging demand both from within the country and from pharma companies looking to outsorucing their manufacturing to India. It already had pharma giants such as Ranbaxy, Dr Reddy's and Sun Pharma as its customers.

More Stories on : Outlook | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
KSL Realty's successful bond offer

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line